Our top pick for
Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure
Grove Inc. Common Stock is a drug manufacturers-specialty & generic business based in the US. Grove IncCommon Stock shares (GRVI) are listed on the NASDAQ and all prices are listed in US Dollars. Grove IncCommon Stock employs 122 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$6.98|
|52-week range||$3.86 - $9.37|
|50-day moving average||$5.27|
|200-day moving average||$5.31|
|Wall St. target price||N/A|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$0.21|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-08)||40.16%|
|1 month (2021-09-16)||30.96%|
|3 months (2021-07-16)||56.50%|
|6 months (2021-04-12)||N/A|
|1 year (2020-10-12)||N/A|
|2 years (2019-10-12)||N/A|
|3 years (2018-10-12)||N/A|
|5 years (2016-10-12)||N/A|
Valuing Grove IncCommon Stock stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Grove IncCommon Stock's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Grove IncCommon Stock's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 24x. In other words, Grove IncCommon Stock shares trade at around 24x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
However, Grove IncCommon Stock's P/E ratio is best considered in relation to those of others within the drug manufacturers-specialty & generic industry or those of similar companies.
Grove IncCommon Stock's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $2.5 million.
The EBITDA is a measure of a Grove IncCommon Stock's overall financial performance and is widely used to measure a its profitability.
To put Grove IncCommon Stock's EBITDA into context you can compare it against that of similar companies.
|Revenue TTM||$24.1 million|
|Operating margin TTM||5.92%|
|Gross profit TTM||$11.9 million|
|Return on assets TTM||5.3%|
|Return on equity TTM||25.46%|
|Market capitalisation||$78.2 million|
TTM: trailing 12 months
There are currently 71,469 Grove IncCommon Stock shares held short by investors – that's known as Grove IncCommon Stock's "short interest". This figure is 44.6% down from 129,056 last month.
There are a few different ways that this level of interest in shorting Grove IncCommon Stock shares can be evaluated.
Grove IncCommon Stock's "short interest ratio" (SIR) is the quantity of Grove IncCommon Stock shares currently shorted divided by the average quantity of Grove IncCommon Stock shares traded daily (recently around 549761.53846154). Grove IncCommon Stock's SIR currently stands at 0.13. In other words for every 100,000 Grove IncCommon Stock shares traded daily on the market, roughly 130 shares are currently held short.
To gain some more context, you can compare Grove IncCommon Stock's short interest ratio against those of similar companies.
However Grove IncCommon Stock's short interest can also be evaluated against the total number of Grove IncCommon Stock shares, or, against the total number of tradable Grove IncCommon Stock shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Grove IncCommon Stock's short interest could be expressed as 0% of the outstanding shares (for every 100,000 Grove IncCommon Stock shares in existence, roughly 0 shares are currently held short) or 0.0103% of the tradable shares (for every 100,000 tradable Grove IncCommon Stock shares, roughly 10 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Grove IncCommon Stock.
Find out more about how you can short Grove IncCommon Stock stock.
We're not expecting Grove IncCommon Stock to pay a dividend over the next 12 months.
Grove, Inc. , through its subsidiaries, engages in developing, producing, marketing, and selling raw materials, white label products, and end consumer products containing the industrial hemp plant extract, cannabidiol. The company serves consumer markets, including the botanical, beauty care, pet care, and functional food sectors. It also operates annual tradeshow related to the CBD industry in the United States. The company was incorporated in 2018 and is headquartered in Henderson, Nevada. .
Everything we know about the Aura Biosciences IPO, plus information on how to buy in.
Everything we know about the Claros Mortgage Trust IPO, plus information on how to buy in.
Everything we know about the Evotec SE IPO, plus information on how to buy in.
Everything we know about the Delimobil Holding SA IPO, plus information on how to buy in.
Everything we know about the Blue Water Vaccines IPO, plus information on how to buy in.
Everything we know about the Sonendo IPO, plus information on how to buy in.
Everything we know about the FlexEnergy Green Solutions IPO, plus information on how to buy in.
Everything we know about the Stran & Company IPO, plus information on how to buy in.
Everything we know about the Kidpik Corp IPO, plus information on how to buy in.
Everything we know about the Nuvectis Pharma IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.